Multiomic Health develops precision medicines for diseases derived from metabolic syndrome by integrating multi-omics data with longitudinal clinical phenotyping. The company uses AI-enabled data science to identify distinct molecular disease drivers within patient subpopulations. This approach enables the origination of therapeutic R&D programs with corresponding patient-stratifying companion diagnostics for higher clinical trial success rates.
Funding
$8.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
HVFounders
Product
Problem
Metabolic syndrome, encompassing conditions like dysglycemia, hypertension, dyslipidemia, and obesity, leads to serious medical complications, including type 2 diabetes, cardiovascular disease, chronic kidney disease and non-alcoholic fatty liver disease. The heterogeneity of these conditions makes drug development challenging, leading to high failure rates in clinical trials and inefficient treatment strategies.
Solution
MultiOmic Health leverages AI-driven multi-omics analysis and computational systems biology to identify distinct molecular drivers within patient subpopulations affected by metabolic syndrome-related diseases. By integrating deep longitudinal patient datasets with AI and experimental biology, the company develops precision therapeutics and companion diagnostics tailored to specific patient profiles. This approach enables the development of targeted therapies and patient-stratifying biomarkers, facilitating shorter, more focused clinical trials with improved success rates. MultiOmic Health is building a drug discovery and development pipeline with corresponding companion diagnostics, with plans to partner with pharmaceutical companies for drug commercialization and laboratory service providers for diagnostic test implementation.
Target Audience
The primary target audience includes pharmaceutical companies seeking novel therapeutics for metabolic syndrome-related diseases, laboratory service providers interested in implementing companion diagnostics, and ultimately, patients suffering from these conditions.
Features
- AI-enabled analysis of multi-omics data (genomics, epigenomics, proteomics, metabolomics) integrated with longitudinal clinical phenotyping
- Identification of patient subpopulations based on distinct molecular-level disease drivers
- Development of patient-stratifying biomarkers to optimize therapeutic response
- Proprietary drug discovery and development pipeline focused on precision therapeutics
- Companion diagnostics development for patient stratification and treatment monitoring